Development of a new class of sulforaphane-enabled self-emulsifying drug delivery systems (SFN-SEDDS) by high throughput screening: A case study with curcumin

2018 ◽  
Vol 539 (1-2) ◽  
pp. 147-156 ◽  
Author(s):  
Mohammad M. Kamal ◽  
Sami Nazzal
2017 ◽  
Vol 106 (4) ◽  
pp. 1183-1186 ◽  
Author(s):  
Mette D. Mosgaard ◽  
Philip J. Sassene ◽  
Huiling Mu ◽  
Thomas Rades ◽  
Anette Müllertz

2018 ◽  
Vol 551 (1-2) ◽  
pp. 84-96
Author(s):  
A. Scano ◽  
F. Ebau ◽  
M.L. Manca ◽  
V. Cabras ◽  
F. Cesare Marincola ◽  
...  

Molecules ◽  
2019 ◽  
Vol 25 (1) ◽  
pp. 3 ◽  
Author(s):  
Fadwa Odeh ◽  
Hamdi Nsairat ◽  
Walhan Alshaer ◽  
Mohammad A. Ismail ◽  
Ezaldeen Esawi ◽  
...  

Soon after they were first described in 1990, aptamers were largely recognized as a new class of biological ligands that can rival antibodies in various analytical, diagnostic, and therapeutic applications. Aptamers are short single-stranded RNA or DNA oligonucleotides capable of folding into complex 3D structures, enabling them to bind to a large variety of targets ranging from small ions to an entire organism. Their high binding specificity and affinity make them comparable to antibodies, but they are superior regarding a longer shelf life, simple production and chemical modification, in addition to low toxicity and immunogenicity. In the past three decades, aptamers have been used in a plethora of therapeutics and drug delivery systems that involve innovative delivery mechanisms and carrying various types of drug cargos. However, the successful translation of aptamer research from bench to bedside has been challenged by several limitations that slow down the realization of promising aptamer applications as therapeutics at the clinical level. The main limitations include the susceptibility to degradation by nucleases, fast renal clearance, low thermal stability, and the limited functional group diversity. The solution to overcome such limitations lies in the chemistry of aptamers. The current review will focus on the recent arts of aptamer chemistry that have been evolved to refine the pharmacological properties of aptamers. Moreover, this review will analyze the advantages and disadvantages of such chemical modifications and how they impact the pharmacological properties of aptamers. Finally, this review will summarize the conjugation strategies of aptamers to nanocarriers for developing targeted drug delivery systems.


2021 ◽  
Vol 22 ◽  
Author(s):  
Arun Radhakrishnan ◽  
Gowthamarajan Kuppusamy

: Individualizing drug therapy and attaining maximum benefits of a drug devoid of adverse reactions is the benefit of personalized medicine. One of the important factors contributing to inter-individual variability is genetic polymorphism. As of now, dose titration is the only followed golden standard for implementing personalized medicine. Converting the genotypic data into an optimized dose has become easier now due to technology development. However, for many drugs, finding an individualized dose may not be successful, which further leads to a trial and error approach. These dose titration strategies are generally followed at the clinical level, and so industrial involvement and further standardizations are not feasible. On the other side, technologically driven pharmaceutical industries have multiple smart drug delivery systems which are underutilized towards personalized medicine. Transdisciplinary research with drug delivery science can additionally support the personalization by converting the traditional concept of “dose titration towards personalization” with novel “dose-cum-dosage form modification towards next-generation personalized medicine”; the latter approach is useful to overcome gene-based inter-individual variability by either blocking, downregulating, or bypassing the biological protein generated by the polymorphic gene. This article elaborates an advanced approach to implement personalized medicine with the support of novel drug delivery systems. As a case study, we further reviewed the genetic polymorphisms associated with tacrolimus and customized novel drug delivery systems to overcome these challenges factored towards personalized medicine for better clinical outcomes, thereby paving a new strategy for implementing personalized medicine for all other drug candidates.


2020 ◽  
Vol 37 (8) ◽  
Author(s):  
Amrita Dikpati ◽  
Farzad Mohammadi ◽  
Karine Greffard ◽  
Caroline Quéant ◽  
Philippe Arnaud ◽  
...  

2010 ◽  
Vol 36 (10) ◽  
pp. 1245-1252 ◽  
Author(s):  
Kenichi Sakai ◽  
Takayuki Yoshimori ◽  
Kouki Obata ◽  
Hiroyuki Maeda

2016 ◽  
Vol 10 (2) ◽  
pp. 159-172 ◽  
Author(s):  
Ihor Tarnavchyk ◽  
◽  
Andriy Voronov ◽  
Volodymyr Donchak ◽  
Olga Budishevska ◽  
...  

The method for synthesis of a new class of amphiphilic oligoesters of pyromellitic acid is developed. As hydrophilic fragments polyethylene glycols or polyethylene glycol mono methyl ethers were used, as lipophilic ones – primary fatty alcohols or cholesterol. The structure of the synthesized oligoesters was confirmed by IR- and PMR-spectroscopy. The oligoesters could solubilize water-insoluble substances, for example such effective antitumor lipophilic drug as curcumin. The high solubilization capacity of the OEPA assemblies and their biodegradability, as well as other properties (size distribution, ζ-potential) make the oligoesters considered as promising materials for the design of drug delivery systems.


Sign in / Sign up

Export Citation Format

Share Document